Sun pharmaceutical industries, Pharmaceutical company

Sun Pharmaceutical Industries said on Friday its US-based subsidiary Taro Pharmaceutical Inc has resolved all cases in connection with multi-year investigations by the Department of Justice's (DoJ's) Anti-trust Division and Civil Division into the US generic pharmaceutical industry.Under a deferred prosecution agreement reached, the DoJ will file information for conduct that took place between 2013 and 2015. If the company adheres to the terms of the agreement, including the payment of 205.7 million dollars, the DoJ will dismiss the information at the end of a three-year period.Taro Pharmaceutical has also reached a framework understanding with the DoJ Civil Division, subject to final agreement and agency authorisation, in which the company has agreed to pay 213.3 million dollars to resolve all claims related to federal healthcare programmes.The company is discussing a separate corporate integrity agreement with the Department of Health and Human Services, Office of Inspector General. This agreement will supplement Taro Pharmaceutical's existing compliance programmes based upon established best practices and industry standards as well as its global code of conduct."We are happy to have reached this global resolution with the DoJ," said Chief Executive Officer Uday Baldota. "Taro Pharmaceutical is committed to the highest level of ethics and integrity and we will continue to fully cooperate with the government on its ongoing investigation into the generic pharmaceutical industry," he said in a statement on Friday.Taro is a science-based pharmaceutical company dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the quality healthcare products.( With inputs from ANI )

Home

City

Latest News

Cricket

LT Premium

National

International

Maharashtra

Opinions

Chhatrapati Sambhajinagar

Nagpur

Entertainment

Photos

Business

Technology

Sports

Lifestyle

Social Viral

Lokmat Games

Health

Pahalgam Terror Attack

Tahawwur Rana

IPL 2025

CM Devendra Fadnavis

Mumbai Local

Weather Update

Sun Pharmaceutical IndustriesFOLLOW

Sun pharmaceutical industries, Latest News

Maharashtra :Sun Pharma shares dip after disappointing Q4 results

Share price of Sun Pharmaceutical Industries slumped by around four per cent on Tuesday, a day after the company announced Rs 2,277.2 crore net loss for the quarter ended March 2022. ...

Business :Sun Pharma posts Q1 consolidated net profit of Rs 1,444 crore

Sun Pharmaceutical Industries on Friday posted a net profit of Rs 1,444 crore for the April to June quarter (Q1 FY22). ...

Business :Sun Pharma clocks Rs 894 crore net profit in March quarter

Sun Pharmaceutical Industries on Thursday posted 124 per cent increase in consolidated net profit at Rs 894 crore for the January to March quarter as compared to Rs 400 crore in the year-ago period. ...

Business :Market in red, indices trim major losses

Mumbai, March 22 The key Indian equity indices traded in the negative territory on Monday morning. The market ... ...

Business :Sun Pharma launches Favipiravir in India for Rs 35 per tablet

Sun Pharmaceutical Industries said on Tuesday it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19. ...

Business :Sun Pharma's arm Taro achieves global resolution of US DoJ anti-trust probes

Sun Pharmaceutical Industries said on Friday its US-based subsidiary Taro Pharmaceutical Inc has resolved all cases in connection with multi-year investigations by the Department of Justice's (DoJ's) Anti-trust Division and Civil Division into the US ...